CLINICAL STUDY ON T-3262

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement9-Clinical; pp. 428 - 432
• Main Authors: WATANABE KAZUYOSHI, KOHARA TOMOO, HAMAMOTO TSUNEO, IKEMOTO HIDEO
• Format: Journal Article
• Language: English
• Published: Japanese Society of Chemotherapy 1988; 公益社団法人 日本化学療法学会
• Subjects: Infectious respiratory disease; new quinolone; T-3262
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.supplement9-clinical_428

T-3262, a new quinolone, was developed by the Research Laboratory of Toyama Chemical Co., Ltd.We carried out the present study to examine the clinical and side effects of T-3262 given to 11 patients with respiratory infection.The subjects were 7 males and 4 females aged 30-77 years (mean 60.5 years). Diseases were acute bronchitis in 7 cases, pneumonia in 2 and bronchiectasis with infection in 2.The dosage of T-3262 was 300 mg twice a day for 5-17 days (mean 8.7 days), a total of 3.0-10.2g (mean total dose 5.24g).Clinically, the effect was excellent in 1 and good in 10 cases. Classified by diseases, T-3262 was good in all 7 cases of acute bronchitis, excellent in 1 and good in 1 of 2 cases of pneumonia, and good in both cases of bronchiectasis with infection. For the bacteriological examination, sputum from 9 patients was cultured.Haemophilus influenzae (3), Staphylococcus aureus (1), Streptococcus pneumoniae (1), Branhamella catarrhalis (1) and Pseudomonas aeruginosa (1) were isolated, and after the administration all isolated microorganisms were be eradicated.No side effects such as drug eruption, fever, nausea, vomiting or diarrhoea were observed and laboratory values were normal before and after the administration of T-3262. 新たに富山化学工業 (株) 綜合研究所で開発されたピリドンカルボン酸系経口合成抗菌剤のT-3262を呼吸器感染症11例に投与し, その臨床効果と副作用などについて検討した。対象症例は男性7例, 女性4例, 年齢分布は30歳より77歳 (平均60.5歳) におよび, 疾患の内訳は急性気管支炎7例, 肺炎2例, 感染を伴った気管支拡張症2例の計11例である。投与方法は全例1回300mg, 1日2回, 食後投与であり, 投与日数は最短5日, 最長17日 (平均投与日数8.7日), 総投与量は3.09より10.29 (平均総投与量5.249) であった。臨床効果は著効1例, 有効10例。疾患別では急性気管支炎7例中7例有効, 肺炎2例中著効1例, 有効1例, 感染を伴った気管支拡張症2例はともに有効であった。細菌学的検討は11例中8例に喀痰培養を試み, インフルエンザ菌 (3例), 黄色ブドウ球菌, 肺炎球菌, プランハメラ・カタラーリス, 緑膿菌を各1例に分離したが, 全例除菌可能であり, 菌交代例は認めなかった。副作用としての消化器症状, アレルギー症状, 中枢神経症状などは全例認めず, また本剤投与による臨床検査値の異常も認めなかった。